Condition: Locally Advanced Rectal Cancer (LARC) · Sponsor: Akamis Bio
The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor for local or distant recurrence.
This description comes directly from the study's public registry record.
Vice President Head of Clinical Operations · +1 (484) 362-8918 · robert.maietta@akamisbio.com
https://www.FortressStudy.org · oliver.rosen@akamisbio.com
Always discuss trial participation with your own doctor first.
| University of Southern California | Los Angeles, California, United States | Active Not Recruiting |
| AdventHealth Orlando | Orlando, Florida, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| University College London NHS FT | London, United Kingdom | Recruiting |
| The Royal Marsden NHS Foundation Trust | Sutton, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06459869